Gan & Lee Pharmaceuticals has officially begun a Phase 1 clinical trial in the United States for ASC36, an investigational oral amylin peptide being developed as a potential treatment for obesity. This milestone adds another promising candidate to the rapidly evolving landscape of peptide-based metabolic therapies, which have already transformed treatment options for weight management and related conditions.
Amylin is a naturally occurring hormone that works alongside insulin to help regulate appetite and glucose levels. By targeting amylin receptor pathways, ASC36 aims to complement or potentially differentiate itself from the GLP-1 class of drugs that have dominated headlines in recent years. Notably, the fact that ASC36 is being developed as an oral formulation—rather than requiring injections—could represent a meaningful convenience advantage for patients if the drug continues to show safety and efficacy in future trials.
Oral peptide delivery has historically been a significant technical challenge, since peptides are often broken down before they can be effectively absorbed by the body. Companies that succeed in developing effective oral versions of these therapies could greatly expand access and improve comfort for patients who prefer avoiding injections altogether. Gan & Lee’s move to bring ASC36 into human trials suggests confidence in their formulation approach and its early preclinical data.
This Phase 1 trial will primarily focus on assessing the safety, tolerability, and pharmacokinetics of ASC36 in human participants—an essential first step before any determination can be made about its long-term effectiveness for obesity treatment. While it is still early in the clinical development process, the initiation of this trial reflects the continued momentum and innovation happening within the peptide therapeutics field, particularly as researchers explore new ways to make metabolic treatments more accessible and easier to use.
As the obesity treatment market continues to expand, differentiated approaches like oral amylin peptides could offer valuable additional options for patients and healthcare providers alike. True North Labs will continue to monitor the progress of ASC36 and similar peptide innovations as they move through the clinical trial pipeline.
This article is for informational purposes only and does not constitute medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Leave a Reply